Interestingly, single drug switching strategy extended the SPFS of HCC patients with AFP<400 ng/ml (HR = 1.89, 95%CI: 1.01–3.55, p = 0.0365), Child-Pugh class A (HR = 2.12, 95%CI: 1.32–3.41, p = 0.0018), absence of macroscopic portal vein invasion (HR = 1.88, 95%CI: 1.05–3.35, p = 0.0275), BCLC stage A or B (HR = 2.78, 95%CI: 1.04–7.45, p = 0.0414), absence of extrahepatic metastasis (HR = 2.48, 95%CI: 1.20–5.14, p = 0.0166), and single progression pattern (HR = 2.45, 95%CI:1.40–4.27, p = 0.0019). The gene discussed is AFP; the disease is hepatocellular carcinoma.